Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

398
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
398
Metastasis02:30

Metastasis

5.4K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.4K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Clinical and racial predictors of adverse pathology at radical prostatectomy: implications for undertreatment among patients receiving radiation and hormonal therapy.

The Canadian journal of urology·2026
Same author

Salvage Androgen Deprivation Therapy Use After Definitive Radiotherapy With vs Without Androgen Deprivation Therapy in Prostate Cancer.

The Prostate·2026
Same author

Understanding Patient Perspectives on Radiation Tattoos.

Advances in radiation oncology·2026
Same author

A Multimodal Artificial Intelligence Model to Guide Use of Whole-Pelvic Radiation Therapy in Patients with Localized Prostate Cancer: Exploratory Analysis of RTOG 9413.

Cancers·2026
Same author

Association Between Cribriform Architecture and Tertiary Gleason Pattern 5 in Prostate Cancer: A Cross-Sectional Study of Radical Prostatectomy Specimens.

Journal of clinical medicine·2026
Same author

Postoperative Pelvic Lymph Node Radiation Therapy in Lymph Node-Positive Prostate Cancer and Mortality Risk.

European urology focus·2026

相关实验视频

Updated: May 10, 2025

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

14.1K

结合转移向的外部束辐射疗法与Lu-PSMA-617在患有晚期割抗性前列腺癌的患者中.

Sedra Mohammadi1, Isabella R Pompa2, Veronica Haberman1

  • 1Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.

Practical radiation oncology
|April 24, 2025
PubMed
概括

针对转移的外部束辐射疗法 (M-EBRT) 在与转移性前列腺癌的卢-177 PSMA (177Lu-PSMA) 疗法相结合时有效控制局部疾病并管理症状. 这种组合显示出良好的耐受性,可能有助于继续治疗.

关键词:
(177) 卢-PSMA-61717 这是一个很好的例子.卢普斯马 (LuPSMA) 是一个在M-EBRT中,它是M-EBRT.组合组合组合的组合组合.mCRPC 的使用情况.

更多相关视频

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model
05:08

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

6.0K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.1K

相关实验视频

Last Updated: May 10, 2025

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

14.1K
Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model
05:08

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

6.0K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.1K

科学领域:

  • 在瘤学瘤学.
  • 放射性药物疗法是一种放射性药物疗法.
  • 辐射瘤学 辐射瘤学

背景情况:

  • 177Lu-PSMA对转移性割抵抗性前列腺癌 (mCRPC) 有效.
  • 在全身治疗的同时,可能需要局部控制转移性疾病.
  • 针对转移的外部束辐射疗法 (M-EBRT) 可以补充LuPSMA.

研究的目的:

  • 评估结合M-EBRT与LuPSMA的指示,疗效和安全性.
  • 评估M-EBRT在接受LuPSMA的患者的局部疾病控制和症状缓解中的作用.

主要方法:

  • 用LuPSMA和M-EBRT治疗的患者的回顾性审查.
  • 对推动M-EBRT使用的临床因素的分析.
  • 与LuPSMA治疗相比,M-EBRT时间的评估.

主要成果:

  • M-EBRT用于内/外皮疾病,骨疼痛缓解和骨折预防.
  • 大多数患者 (62%) 在M-EBRT后经历了症状缓解.
  • 前列腺特异性抗原 (PSA) 50反应为41%,具有异质的幅度.

结论:

  • M-EBRT是LuPSMA的有效补充,用于局部瘤控制和症状管理,特别是骨和中枢神经系统病变.
  • 组合疗法表现出良好的耐受性.
  • M-EBRT可能有助于启动或继续LuPSMA治疗.